Vascular Adverse Events During Long-term Nilotinib Therapy in Patients With Chronic Myeloid Leukemia

The treatment of patients with chronic myeloid leukemia in the chronic phase (CML-CP) has changed dramatically in the era of tyrosine kinase inhibitors (TKIs).1 Although most patients will achieve and maintain optimal molecular and cytogenetic responses with TKI therapy, long-term tyrosine kinase inhibition is not without toxicities.2 Cardiovascular events can develop during TKI therapy, mainly in patients with pre-existing cardiovascular disease (CVD) risk factors. Because the life expectancy of patients with CML-CP has increased in this new era, adverse events from TKIs, including CVD, can be challenging for both patients and physicians.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research